<DOC>
	<DOCNO>NCT00873366</DOCNO>
	<brief_summary>RATIONALE : A breath test measure enzyme may effective identify woman tamoxifen may effective . PURPOSE : This clinical trial study breath test see well work woman receive tamoxifen prevention treatment breast cancer .</brief_summary>
	<brief_title>Breath Test Women Receiving Tamoxifen Prevention Treatment Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To assess operate characteristic ¹³C-dextromethorphan ( ^13 C-DM ) breath test identify woman breast cancer ( high risk ) CYP2D6-genotypic poor metabolizers . - To examine correlation CYP2D6 enzyme activity ( measure breath test ) plasma endoxifen ( 4-hydroxyTAM ) level patient carry one CYP2D6 functional allele . - To examine change CYP2D6 enzyme activity ( measure ¹³C-DM breath test ) , patient start CYP2D6 inhibitor take tamoxifen . - To determine whether CYP2D6 enzyme activity ( measure breath test ) change time ( either consequence drug-induced inhibition ) . - To measure genetic variation additional gene later identify affect metabolism , uptake , distribution tamoxifen ( e.g. , SULT1A1 , UGT ) . OUTLINE : Patients receive tamoxifen citrate 6 month . ^13C-dextromethorphan breath test conduct baseline periodically 6 month . 13C-dextromethorphan breath test : Patients receive oral Alka-Seltzer® Gold ( ASG ; citric acid , potassium bicarbonate , sodium bicarbonate ) water , , 15 minute later , another ASG dose oral ¹³C-dextromethorphan . Patients breathe bag 1-2 time , bag seal . ¹³CO_2 level bag measure . Blood sample collect baseline periodically pharmacogenetic pharmacokinetic study reverse phase HPLC fluorescence detection . After completion study therapy , patient follow annually 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Eligible receive tamoxifen 6 month either prevention treatment noninvasive invasive , stage IIII breast cancer CYP2D6 genotype know Patients determine CYP2D6 poor metabolizers ( determination genotype test Mayo physician prior study registration ) eligible proceed initial breath test Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify ECOG performance status 02 Life expectancy &gt; 6 month No know impaired hepatic activity define ≥ grade 3 AST , alkaline phosphatase , total bilirubin No pulmonary disease ( e.g. , asthma respiratory disease ) associate hypercapnia No uncontrolled metabolic disease ( e.g. , diabetes presence gastroparesis , uncontrolled congestive heart failure , uncontrolled gastrointestinal disorder [ e.g. , GERD ] ) No prior adverse reaction dextromethorphan No history chronic liver disease ( e.g. , hepatitis B hepatitis C , alcoholic liver disease , cirrhosis , fibrotic disease ) Able willing fast overnight prior study session Willing return Mayo Clinic followup Willing provide biologic specimens PRIOR CONCURRENT THERAPY : More 24 hour since prior medication know slow gastric empty gastrointestinal motility ( e.g. , alcohol , opioid analgesic , anticholinergic [ e.g. , antihistamine ] , loperamide ) More 4 week since prior concurrent CYP2D6 inhibitor concurrent serotoninreuptake inhibitor know potent CYP2D6 inhibitor ( e.g. , paroxetine [ Paxil® ] fluoxetine [ Prozac® ] If mild moderate inhibitor CYP2D6 medically necessary , patient may go back 8week time point More 4 week since prior concurrent monoamineoxidase inhibitor ( e.g. , furazolidone , phenelzine , procarbazine , selegiline , tranylcypromine )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>